ArticleNature2021
Clonal fitness inferred from time-series modelling of single-cell cancer genomes.
Open access · greenAbstract read
In one paragraph
Article in Nature, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 92 papers.
0numbers the graph read from it
0cells of the map it votes in
92citing papers in PubMed
13.2field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
92 citing papers in PubMed, 167 citations in OpenAlex.
- Article
- Review
- A guide to understanding tumour evolution through the lens of population genetics.Nature reviews. Cancer · 2026Review
- Direct estimation of genotype fitness from time series.bioRxiv : the preprint server for biology · 2026Article
- LeafRank: A phylodynamic framework for inferring relative fitness from single-cell phylogenies in chromosomally unstable tumors.bioRxiv : the preprint server for biology · 2026Article
- Multifunctional nanotherapeutics for targeted modulation of endoplasmic reticulum stress to potentiate cancer therapy.Asian journal of pharmaceutical sciences · 2026Review
- tugMedi: simulator of cancer-cell evolution for personalized medicine based on the genomic data of patients.NPJ systems biology and applications · 2026Article
- Inferring tumor absolute copy number and clonal substructure from single-cell chromatin accessibility.Briefings in bioinformatics · 2026Article
- Integrated Single-Cell Whole-Genome Sequencing and Spatial Transcriptomics Reveal Intratumoral Heterogeneity in Ovarian Cancer.Cancer research communications · 2026Article
- Evolution of oncogene amplification across 86,000 cancer cell genomes.bioRxiv : the preprint server for biology · 2026Article
- Deciphering double-negative prostate cancer: from aggressive subtype to novel therapeutic paradigms.Cell communication and signaling : CCS · 2026Review
- Evolutionary dynamics under phenotypic uncertainty.bioRxiv : the preprint server for biology · 2026Article
- Inverse game theory characterizes frequency-dependent selection driven by karyotypic diversity in triple-negative breast cancer.PLoS computational biology · 2026Article
- Negative Selection Maintains Grossly Altered but Broadly Stable Karyotypes in Metastatic Colorectal Cancer.Cancer discovery · 2026Article
- Strength through diversity: how cancers thrive when clones cooperate.Molecular oncology · 2026Review
- ALFA-K: Local adaptive mapping of karyotype fitness landscapes.Nature communications · 2025Article
- SISTEM: simulation of tumor evolution, metastasis, and DNA-seq data under genotype-driven selection.Bioinformatics (Oxford, England) · 2025Article
- Selection Estimation from Genetic Time-Series Data: Effects of Limited Sampling and Genetic Drift.Molecular biology and evolution · 2025Article
- Article
- Large-scale single-cell phylogenetic mapping of clonal evolution in the human aging esophagus.bioRxiv : the preprint server for biology · 2025Article
32 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
- Commented on by
Authors and funding
34 authors at 11 institutions in 4 countries.
Sohrab Salehi *Department of Molecular Oncology, BC Cancer, Vancouver, British Columbia, Canada.
Farhia Kabeer *Department of Molecular Oncology, BC Cancer, Vancouver, British Columbia, Canada.
Nicholas CegliaComputational Oncology, Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Mirela AndronescuDepartment of Molecular Oncology, BC Cancer, Vancouver, British Columbia, Canada.
Marc J WilliamsComputational Oncology, Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY, USA.ORCID http://orcid.org/0000-0001-5524-4174
Kieran R CampbellLunenfeld-Tanenbaum Research Institute Mount Sinai Hospital Joseph & Wolf Lebovic Health Complex, Molecular Genetics, University of Toronto, Toronto, Ontario, Canada.ORCID http://orcid.org/0000-0003-1981-5763
Tehmina MasudDepartment of Molecular Oncology, BC Cancer, Vancouver, British Columbia, Canada.
Beixi WangDepartment of Molecular Oncology, BC Cancer, Vancouver, British Columbia, Canada.
Justina BieleDepartment of Molecular Oncology, BC Cancer, Vancouver, British Columbia, Canada.
Jazmine BrimhallDepartment of Molecular Oncology, BC Cancer, Vancouver, British Columbia, Canada.
David GeeDepartment of Molecular Oncology, BC Cancer, Vancouver, British Columbia, Canada.
Hakwoo LeeDepartment of Molecular Oncology, BC Cancer, Vancouver, British Columbia, Canada.
Jerome TingDepartment of Molecular Oncology, BC Cancer, Vancouver, British Columbia, Canada.
Allen W ZhangDepartment of Molecular Oncology, BC Cancer, Vancouver, British Columbia, Canada.ORCID http://orcid.org/0000-0002-7606-089X
Hoa TranDepartment of Molecular Oncology, BC Cancer, Vancouver, British Columbia, Canada.ORCID http://orcid.org/0000-0002-9547-8650
Ciara O'FlanaganDepartment of Molecular Oncology, BC Cancer, Vancouver, British Columbia, Canada.
Fatemeh DorriDepartment of Molecular Oncology, BC Cancer, Vancouver, British Columbia, Canada.
Nicole RuskComputational Oncology, Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY, USA.ORCID http://orcid.org/0000-0003-2663-6288
Teresa Ruiz de AlgaraDepartment of Molecular Oncology, BC Cancer, Vancouver, British Columbia, Canada.
So Ra LeeDepartment of Molecular Oncology, BC Cancer, Vancouver, British Columbia, Canada.
Brian Yu Chieh ChengDepartment of Molecular Oncology, BC Cancer, Vancouver, British Columbia, Canada.ORCID http://orcid.org/0000-0002-9258-8184
Peter EirewDepartment of Molecular Oncology, BC Cancer, Vancouver, British Columbia, Canada.
Takako KonoDepartment of Molecular Oncology, BC Cancer, Vancouver, British Columbia, Canada.
Jenifer PhamDepartment of Molecular Oncology, BC Cancer, Vancouver, British Columbia, Canada.
Diljot GrewalComputational Oncology, Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Daniel LaiDepartment of Molecular Oncology, BC Cancer, Vancouver, British Columbia, Canada.ORCID http://orcid.org/0000-0001-9203-6323
Richard MooreCanada's Michael Smith Genome Sciences Centre, BC Cancer, Vancouver, British Columbia, Canada.
Andrew J MungallCanada's Michael Smith Genome Sciences Centre, BC Cancer, Vancouver, British Columbia, Canada.
Marco A MarraCanada's Michael Smith Genome Sciences Centre, BC Cancer, Vancouver, British Columbia, Canada.ORCID http://orcid.org/0000-0001-7146-7175
IMAXT Consortium
Andrew McPhersonComputational Oncology, Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Alexandre Bouchard-CôtéDepartment of Statistics, University of British Columbia, Vancouver, British Columbia, Canada.
Samuel AparicioDepartment of Molecular Oncology, BC Cancer, Vancouver, British Columbia, Canada. saparicio@bccrc.ca.ORCID http://orcid.org/0000-0002-0487-9599
Sohrab P ShahComputational Oncology, Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY, USA. shahs3@mskcc.org.ORCID http://orcid.org/0000-0001-6402-523X
University of Cambridge · GBMcGovern Institute for Brain Research · USMemorial Sloan Kettering Cancer Center · USUniversity of British Columbia · CAHoward Hughes Medical Institute · USUniversity of Zurich · CHCanada's Michael Smith Genome Sciences Centre · CALudwig Cancer Research · USLudwig Cancer Research · CHMount Sinai Hospital · CABC Cancer Agency · CA
Funding
X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Hongbiao Carl Lekaye · 1985 to 2026
$347.4MCenter for Integrated Cellular Analysis - Valeria A. Sanchez EstradaRM1HG011014 · NHGRI · NEW YORK GENOME CENTER · PI LANDAU, DAN, SATIJA, RAHUL · 2020 to 2025
$22.1MTargeting Polθ to Overcome PARP Inhibitor Resistance in Homologous Recombination Deficient Breast CancerP50CA247749 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI Simon N. Powell · 2020 to 2026
$16.3MCancer Research UK 21143Medical Research Council MR/M008975/1NCI NIH HHS P30 CA008748NCI NIH HHS P50 CA247749NHGRI NIH HHS RM1 HG011014
Abstract
Progress in defining genomic fitness landscapes in cancer, especially those defined by copy number alterations (CNAs), has been impeded by lack of time-series single-cell sampling of polyclonal populations and temporal statistical models
Indexed as
DNA Copy Number VariationsDrug Resistance, NeoplasmAnimalsCell Line, TumorCisplatinClone CellsFemaleGenetic FitnessHumansMiceModels, StatisticalNeoplasm TransplantationTriple Negative Breast NeoplasmsTumor Suppressor Protein p53Whole Genome SequencingCisplatinTP53 protein, humanTumor Suppressor Protein p53
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.